Travel and Leisure Travel and Leisure
Fri, May 16, 2025
[ Yesterday Evening ] - wtvr
Strengthen your mental fitness
[ Yesterday Evening ] - KITV
Fire extinguished at a Kalihi house
[ Yesterday Afternoon ] - Chowhound
Can You Buy Lamb At Whole Foods?
[ Yesterday Morning ] - Fortune
CD rates today, May 16, 2025

Ozempic CEO's exit from Novo started with Teams call surprise


Published on 2025-05-16 15:06:51 - Fortune
  Print publication without navigation

  • "I think that's part of the game, so to say. It's not for me to judge the criteria," Lars Fruergaard Jorgensen said.

Novo Nordisk's CEO, Lars Fruergaard Jørgensen, announced his unexpected departure from the company, effective immediately, as reported by Fortune on May 16, 2025. Jørgensen, who has been at the helm since 2017, led the company through a period of significant growth, particularly with the success of its diabetes and weight-loss drugs, Ozempic and Wegovy. His exit comes as a surprise to the industry, with no specific reason given for his sudden departure. The board has appointed Karsten Munk Knudsen, the current executive vice president and head of commercial strategy and corporate development, as the interim CEO while a search for a permanent replacement is conducted. The transition is expected to be smooth, but investors and analysts are closely watching how this leadership change will impact the company's future strategy and performance.

Read the Full Fortune Article at:
[ https://fortune.com/2025/05/16/novo-nordisk-ozempic-wegovy-ceo-jorgensen-exit-surprise/ ]